Department of Pediatrics, Division of Gastroenterology, Seattle Children's Hospital and University of Washington, Seattle, WA 98105, USA.
Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.
Nutrients. 2020 Dec 6;12(12):3749. doi: 10.3390/nu12123749.
Crohn's disease (CD) is a chronic inflammatory intestinal disorder associated with intestinal dysbiosis. Diet modulates the intestinal microbiome and therefore has a therapeutic potential. The aim of this study is to determine the potential efficacy of three versions of the specific carbohydrate diet (SCD) in active Crohn's Disease.
18 patients with mild/moderate CD (PCDAI 15-45) aged 7 to 18 years were enrolled. Patients were randomized to either SCD, modified SCD(MSCD) or whole foods (WF) diet. Patients were evaluated at baseline, 2, 4, 8 and 12 weeks. PCDAI, inflammatory labs and multi-omics evaluations were assessed.
Mean age was 14.3 ± 2.9 years. At week 12, all participants (n = 10) who completed the study achieved clinical remission. The C-reactive protein decreased from 1.3 ± 0.7 at enrollment to 0.9 ± 0.5 at 12 weeks in the SCD group. In the MSCD group, the CRP decreased from 1.6 ± 1.1 at enrollment to 0.7 ± 0.1 at 12 weeks. In the WF group, the CRP decreased from 3.9 ± 4.3 at enrollment to 1.6 ± 1.3 at 12 weeks. In addition, the microbiome composition shifted in all patients across the study period. While the nature of the changes was largely patient specific, the predicted metabolic mode of the organisms increasing and decreasing in activity was consistent across patients.
This study emphasizes the impact of diet in CD. Each diet had a positive effect on symptoms and inflammatory burden; the more exclusionary diets were associated with a better resolution of inflammation.
克罗恩病(CD)是一种与肠道菌群失调相关的慢性炎症性肠道疾病。饮食可以调节肠道微生物群,因此具有治疗潜力。本研究旨在确定三种特定碳水化合物饮食(SCD)版本在活动性 CD 中的潜在疗效。
纳入 18 名年龄在 7 至 18 岁的轻度/中度 CD(PCDAI 15-45)患者。患者被随机分为 SCD、改良 SCD(MSCD)或全食物(WF)饮食组。患者在基线、2、4、8 和 12 周进行评估。评估 PCDAI、炎症实验室和多组学评估。
平均年龄为 14.3 ± 2.9 岁。在第 12 周,所有完成研究的参与者(n = 10)均达到临床缓解。SCD 组的 C 反应蛋白(CRP)从入组时的 1.3 ± 0.7 降至 12 周时的 0.9 ± 0.5。MSCD 组的 CRP 从入组时的 1.6 ± 1.1 降至 12 周时的 0.7 ± 0.1。WF 组的 CRP 从入组时的 3.9 ± 4.3 降至 12 周时的 1.6 ± 1.3。此外,在整个研究期间,所有患者的微生物组组成都发生了变化。虽然变化的性质在很大程度上是特定于患者的,但预测的代谢模式是一致的,即增加和减少活性的生物体。
本研究强调了饮食在 CD 中的作用。每种饮食对症状和炎症负担都有积极影响;更具排他性的饮食与炎症的更好缓解相关。